Janardan Pandey to Antibodies, Monoclonal
This is a "connection" page, showing publications Janardan Pandey has written about Antibodies, Monoclonal.
Connection Strength
1.147
-
Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes. MAbs. 2012 Sep-Oct; 4(5):553-4.
Score: 0.325
-
Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. Clin Exp Immunol. 2011 Dec; 166(3):361-5.
Score: 0.311
-
IgG3 constant region GM (? marker) allotypes could influence the neutralizing potency of anti-SARS-CoV-2 monoclonal antibodies. Proc Natl Acad Sci U S A. 2022 02 08; 119(6).
Score: 0.158
-
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 2019 10; 6(10):e667-e679.
Score: 0.133
-
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018 01; 15(1):e1002493.
Score: 0.119
-
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015 Dec; 182(3):289-301.
Score: 0.101